MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...
Clinically meaningful MG-ADL response (≥2-point reduction) occurred in 69% of treated patients, exceeding the 53% response ...
Hosted on MSN
Understanding the MG activities of daily living (MG-ADL) scale and what it means for your myasthenia gravis treatment
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that causes muscle weakness that worsens with activity and often fluctuates throughout the day. Symptoms may include drooping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results